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Chondroitin sulphate proteoglycans (CSPGs) are known to be important contributors to the intensely inhibitory
environment that prevents tissue repair and regeneration following spinal cord injury. The bacterial enzyme
chondroitinase ABC (ChABC) degrades these inhibitory molecules and has repeatedly been shown to promote
functional recovery in a number of spinal cord injury models. However, when used to treat more traumatic
and clinically relevant spinal contusion injuries, ﬁndingswith the ChABC enzyme have been inconsistent. We re-
cently demonstrated that delivery ofmammalian-compatible ChABC via gene therapy led to sustained andwide-
spread digestion of CSPGs, resulting in signiﬁcant functional repair of a moderate thoracic contusion injury in
adult rats. Here we demonstrate that chondroitinase gene therapy signiﬁcantly enhances upper limb function
following cervical contusion injury, with improved forelimb ladder performance and grip strength as well as in-
creased spinal conduction through the injury site and reduced lesion pathology. This is an important addition to
our previous ﬁndings as improving upper limb function is a top priority for spinal injured patients. Additionally
great importance is placed on replication in the spinal cord injury ﬁeld. That chondroitinase gene therapy has
now been shown to be efﬁcacious in contusion models at either thoracic or cervical level is an important step
in the further development of this promising therapeutic strategy towards the clinic.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Spinal cord injury (SCI) is a devastating condition, leading to varying
degrees of motor, sensory and autonomic deﬁcits and for which there is
currently no adequate treatment. Following the initial trauma to the spi-
nal cord, complex pathological interactions lead to a cascade of second-
ary damage which results in the establishment of a peri-lesional area
which potently inhibits axonal growth and spinal repair (Hagg and
Oudega, 2006). This is one of themain reasons for the lack of functional
recovery following SCI. Chondroitin sulphate proteoglycans (CSPGs) are
known to contribute to the intensely inhibitory environment present at
the lesion site, where they are heavily upregulated following SCI,
preventing effective regeneration or repair of the damaged spinal cord
(Cregg et al., 2014). In addition to being upregulated at the injury site,
CSPGs are also present throughout the central nervous system as part
of the extracellular matrix. The use of the bacterial enzyme
chondroitinase ABC (ChABC) to breakdown CSPGs has repeatedly been
shown to have beneﬁcial effects on spinal repair following traumatic inju-
ry bynumerous different research groups and in a number of different an-
imal species and injury models (Ramer et al., 2014; Garcia-Alias et al.,
2009; Bradbury et al., 2002; Alilain et al., 2011).
We have recently demonstrated that using a lentiviral vector to
deliver a modiﬁed mammalian-compatible ChABC gene to the adult
mammalian spinal cord results in endogenous expression of active
enzyme, leading to long-term and widespread degradation of CSPGs
(Bartus et al., 2014). Moreover, this single delivery gene therapy ap-
proach resulted in extensive remodelling of the extracellular matrix
and alterations to the post-injury inﬂammatory response. These chang-
es were associated with dramatic improvements in tissue pathology,
conduction of long distance spinal sensory axons and skilled hindlimb
locomotion following a thoracic contusion injury, an injury model in
which treatment with bacterial ChABC enzyme had previously met
with limited success (Iseda et al., 2008; Tom et al., 2009).
Wenowaim to determine if this treatment can be successfully trans-
lated to amore clinically relevant cervical contusion injurymodel. Since
replication is important for the SCI ﬁeld (Steward et al., 2012), we will
assess whether we can replicate our previous ﬁndings in a higher level
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more severe injury model affecting forelimb function. Assessing the
efﬁcacy of our treatment in this model is important since just over half
of all human SCIs occur at the cervical level, making it themost common
injury level (followed by thoracic injury which represents ~35% of SCI
patients; www.nscisc.uab.edu) and over a quarter of all spinal injured
patients have suffered from a contusive-type injury at this level. There-
fore, cervical contusion models are highly relevant pre-clinical models
of SCI. These models also allow the study of impairments to upper
limb function which is one of the highest priority functions for patients
with SCI (Anderson, 2004). Our results show that ChABC gene therapy
leads to signiﬁcant anatomical and functional repair following cervical
contusion injury. Importantly treatment led to signiﬁcant improve-
ments in upper limb and hand function, shown using assessments of
skilled locomotion and forelimb grip tasks.
2. Methods
2.1. Animals
Adult male Sprague-Dawley rats (230–250 g; Harlan laboratories)
were used (housed under a 12 hour light/dark cycle with free access
to food and water). All experimental procedures were performed in
accordance with the U.K. Animals (Surgical Procedures) Act 1996.
Behavioural testing, electrophysiology and histological analyses were
all performed by experimenters blinded to treatment. Randomisation
to assign animals to treatment groups was carried out by an individual
playing no further role in the study, as were intraspinal injections of
each treatment. A total of 24 animals were used with n = 8 assigned
to each treatment group (contusion only, contusion + LV-GFP and
contusion + LV-ChABC). All animals were assessed behaviourally and
n = 5/group were used for the electrophysiological and histological
assessments.
2.2. Chondroitinase gene and lentiviral vectors
The Proteus vulgaris ChABC gene was modiﬁed with mutations
targeted to remove ﬁve cryptic N-glycosylation sites and addition of a
mammalian signal sequence and resynthesised with mammalian pre-
ferred codons to make a mammalian-compatible engineered ChABC
gene (Muir et al., 2010). The modiﬁed ChABC cDNA was subcloned into
a lentiviral transfer vector (termed LV-ChABC) with the mouse phospho-
glycerate kinase promoter, as previously described (Bartus et al., 2014).
The resulting vector was integrating, self-inactivating and pseudotyped
with VSV-G. Viral particles were concentrated by ultracentrifugation
and titered by a p24 antigen ELISA assay. The viral titer was 479 μg/ml
of P24, corresponding to ~106 TU/μl. A control lentiviral vector (termed
LV-GFP) was generated from the same transfer vector containing the
cDNA coding for GFP, with a viral titer of 346 μg/ml of P24.
2.3. Contusion injury surgery and treatment
Male adult rats were anaesthetized (ketamine, 60 mg/kg, and
medetomidine, 0.25 mg/kg), the cervical region of their backs were
shaved and cleansedwith iodine and core temperature wasmaintained
close to 37 °C using a self-regulating heated blanket. A laminectomywas
then performed at vertebral level C5 to expose the underlying spinal
cord. Animals were then positioned and stabilised with the impactor
probe of an Inﬁnite Horizon impactor (Precision Systems Instrumenta-
tion, Lexington, KY) positioned 3–4 mm above the exposed spinal
cord. The impactor probe then delivered an impact force of 225 kdyne
to the spinal cord, inducing a moderate cervical (C5) contusion injury.
Following injury, rats designated to a contusion only group had their
wounds sutured and anaesthesia was then reversed using atipamezole
hydrochloride (1 mg/kg administered i.p.). All other animals received
0.5 μl intraspinal injections of either LV-GFP or LV-ChABC immediately
rostral and caudal to the contusion injury (one injection either
side). Injections were delivered at a rate of 200 nl/min using an
ultra micropump III (World Precisions Instrumentation, Europe).
Following intraspinal injection, wounds were closed and anaesthesia
was reversed. All animals received post-operative analgesia (carprofen
mg/kg) for two days, saline for rehydration (3–5 ml) for three days, and
a one week course of antibiotics (baytril; mg/kg).
2.4. Behavioural assessments
Animals were trained in all behavioural tasks for one week prior to
surgery and were assessed on the day prior to surgery to provide base-
line data for each task. Assessments were then carried out on a weekly
basis post-surgery by an experimenter blinded to treatment group.
Skilled locomotion and sensorimotor integration were assessed
using the horizontal ladder test. This involved counting the total num-
ber of both forelimb and hindlimb footslips made by each animal over
the course of three runs across a 1m ladderwith unevenly spaced rungs.
Forelimb grip-strength was assessed using a forelimb grip-strength
meter (Linton Instrumentation). This involved rats grasping onto a
metal barwith their forepaws,whichwas attached to a force transducer,
and slowly being pulled backwardswith gradually increasing force until
the rat could no longer hold on andwould then release thebar. The grip-
strength meter gave a readout of the maximum force applied to the
force transducer (i.e. the force at which the rat could no longer grip
the bar) and this was recorded. An average was taken from three grip-
strength readouts per session.
For the inclined plane task animals were placed horizontally on a
rubberised surface (to provide traction) initially held at an angle of
40°. If the rat could hold its position, with no signs of slipping, for 4 s
then the incline was increased by 5°. This process was repeated until
the incline reached an angle at which the rat could no longer stay sta-
tionary and began to slip. This was repeated twicemore and an average
angle of incline at which the rat began to slip was calculated from the
three scores.
2.5. Electrophysiological assessment of sensory function
Axonal conductionwas assessed by antidromic stimulation of senso-
ry ﬁbres in the dorsal columns in terminal electrophysiology experi-
ments, using a method adapted from a previous study (James et al.,
2011). The spinal cord was exposed from C2 to T1 and T13 to L5 (verte-
bral levels) in urethane-anaesthetized rats (1.25 g/kg). Antidromic uni-
tary activity was recorded and quantiﬁed from teased dorsal root
ﬁlaments (left and right L3–S1 roots), whilst ﬁrst stimulating the entire
dorsal columns 5 mm below and then 5 mm above the injury site.
Conduction through the injury site was measured by calculating the
number of single units present when stimulating above the injury site
as a percentage of the total number of single units when stimulating
below. Stimulation was continuous during recording sessions and was
carried out using 0.2 ms duration, square wave pulses at a frequency
of 1 Hz and an incrementally increasing intensity (0–800 μA). Stimula-
tion was maximal by 400–500 μA (i.e. no further unitary activity could
be recruited), but continued to be increased to 800 μA to ensure that
no high-threshold ﬁbres were undetected.
2.6. Histological assessment of cavity size
Tissue preparation and eriochrome cyanine histochemistry were
performed as previously described (James et al., 2011). Sections were
examined using a Zeiss Axioskop microscope and pictures were taken
of sections at 800 μm intervals throughout the lesion site using a Zeiss
AxioCam MRm. Images were analysed using Axiovision software,
which allowed the tracing of the spinal cord perimeter and any cavity
for each image captured, giving the total area for these measurements
in each section. The lesion epicentre was deﬁned as the section from
each animal with the largest cavity area and quantiﬁcation was carried
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out at 800 μm intervals from 2.4 mm caudal to 2.4 mm rostral to the
epicentre. The cavity area was calculated as a percentage of spinal
cord area (i.e. area within the tracing of spinal cord perimeter) for
each section.
2.7. Statistical analysis
All numerical values are reported asmean± s.e.m. and all statistical
analyses were carried out using GraphPad Prism v5 software. Behav-
ioural and histological data were analysed using two-way repeated
measures ANOVA, electrophysiological data was analysed by one-way
ANOVA. Post-hoc comparisons were carried out where appropriate
and all statistical tests are stated in the text.
3. Results
3.1. Chondroitinase gene therapy promotes recovery of upper limb function
Following treatment of a 225 kdyne C5 contusion with LV-ChABC,
signiﬁcant functional improvements in skilled forelimb and hindlimb
locomotion were detected when assessed using the horizontal ladder
(Fig. 1A and B). Animals treated with LV-ChABC displayed signiﬁcantly
improved functional recovery on the horizontal ladder compared to all
other treatment groups at all post-injury time points beyond 3 weeks
(p b 0.01; two-way RM ANOVA, Bonferroni post-hoc), such that by
10 weeks post-injury LV-ChABC treated animals were making 33.3 ±
2.2 forelimb and 19.6 ± 2.1 hindlimb slips compared to 54.1 ± 6.1
and 29.4 ± 1.2 for contusion only and 61.7 ± 3 and 30.3 ± 2.8 for
contusion + LV-GFP. LV-ChABC treated animals also displayed sig-
niﬁcant improvements in forelimb grip-strength compared to all
other treatment groups (Fig. 1C; p b 0.05, two-way RM ANOVA). At
10 weeks post-injury LV-ChABC treated animals were capable of
exerting a grip-strength of 409.8 ± 70.3 g, whilst LV-GFP treated and
contusion only animals achieved forces of only 296.2 ± 53.1 g and
299.7 ± 42.7 g, respectively. There were no detectable differences be-
tween groups when comparing proprioceptive function using the in-
clined plane task (Fig. 1D). These results indicate that LV-ChABC leads
to signiﬁcant improvements in both upper and lower limb functions fol-
lowing a cervical contusion injury.
3.2. Chondroitinase gene therapy leads to improved long distance axonal
conduction through a cervical contusion site
Electrophysiological experiments were next performed in order to
assess the extent of long distance, axonal conduction across the cervical
contusion site. The antidromic activation of sensory dorsal column ﬁ-
bres caudal to the injury site allowed the recording of unitary activity
from thin ﬁlaments teased from lumbar dorsal roots (James et al.,
2011). Conduction through the injury site could then be assessed by
switching stimulation to a site just rostral to the lesion and determining
the percentage of single units still present in each dorsal root ﬁlament.
LV-ChABC treated animals displayed signiﬁcantly improved levels of
Fig. 1. Chondroitinase gene therapy leads to signiﬁcant improvements in upper limb and hand function, spinal conduction and tissue pathology. LV-ChABC signiﬁcantly improves recovery
of skilled locomotor function in forelimbs (A) and hindlimbs (B) in comparison to contusion only or treatment with LV-GFP (p b 0.01, two-way RM ANOVA, Bonferroni post-hoc).
(C) Signiﬁcant improvements in comparison to both control groups are also detected following assessment of forelimb grip-strength in LV-ChABC treated animals (p b 0.05, two-way
RM ANOVA), but no differences are detected in proprioceptive function as assessed by the inclined plane task (D). (E) LV-ChABC treated animals display dramatic improvements in con-
duction of longdistance sensory axons through the cervical contusion injury sitewhen assessed electrophysiologically (p b 0.001, one-wayANOVA, Tukey's post hoc). LV-ChABC treatment
(I) results in a signiﬁcant reduction of cavity size at the injury epicentre and a reduction in its rostral spread (F) when compared with contusion only (G) and LV-GFP treatment
(H) (p b 0.05, two-way RM ANOVA, Bonferroni post-hoc). n = 8/group A–D, n = 5/group E and F. Scale bar represents 1 mm (G–I).
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conduction through the injury site in comparison to all other treatment
groups (16.7 ± 1.6% compared to 4.7 ± 1.6% and 4.3 ± 1.8% for contu-
sion only and contusion + LV-GFP, respectively; p = 0.001, one-way
ANOVA, Tukey's post-hoc; Fig. 1E). These ﬁndings highlight a dramatic
improvement in the functionality of the spinal cord's major sensory
pathway following cervical contusion and treatment with LV-ChABC.
3.3. Chondroitinase gene therapy leads to reduced tissue pathology
In order to assess anatomical changes due to treatment with
LV-ChABC, erichrome cyanine staining was performed on histological
tissue sections to allow quantiﬁcation of cavity formation at the lesion
epicentre and the rostro-caudal spread of tissue damage (Fig. 1F–I).
Overall cavity development in LV-ChABC treated animals (Fig. 1I) was
signiﬁcantly reduced in comparison with contusion only (Fig. 1G)
and LV-GFP (Fig. 1H) treated animals (p b 0.01 two-way RM ANOVA;
Fig. 1F). The most signiﬁcant reduction in cavity size was apparent at
the lesion epicentre, such that at its largest the cavity in LV-ChABC treat-
ed animals was approximately half the size of the cavities which devel-
oped in the two control groups (13.3 ± 2.9% compared to 24.4 ± 2.3%
and 21.3 ± 3.3% for contusion only and LV-GFP, respectively; p b 0.05,
Bonferroni post-hoc; Fig. 1F). In addition, there was a reduction in the
spread of cavity development from the lesion epicentre in LV-ChABC
treated animals such that there was minimal cavity present at 0.8 mm
rostral or caudal to the epicentre in LV-ChABC treated animals, whilst
in contusion only and LV-GFP treated animals cavitieswere still approx-
imately 10% of the total cord area in these tissue sections (Fig. 1F;
p b 0.05 at 0.8 mm rostral of epicentre, Bonferroni post-hoc).
4. Discussion
Here we demonstrate that ChABC gene therapy is effective when
used in a model of cervical contusion injury. This marks an important
step in demonstrating the potential for this treatment to be further de-
veloped towards clinical translation. Behavioural analyses demonstrat-
ed signiﬁcant improvements in both forelimb and hindlimb function
during skilled locomotion as well as improved forelimb grip-strength.
Additionally, terminal electrophysiological experiments highlighted
dramatically improved functionality in the main sensory pathway of
the spinal cord. These functional improvements were complimented
by anatomical observations indicating that there was signiﬁcantly re-
duced cavity formation in animals receiving ChABC gene delivery. That
this treatment has now been shown to lead to functional and patholog-
ical improvements in contusion injuries at thoracic (Bartus et al., 2014)
or cervical levels indicates that the effects of LV-ChABC are robust, a pos-
itive sign if this treatment is to be successfully translated. Furthermore,
the use of a contusion injury model at cervical level in this study is of
critical importance, as this is the most frequently occurring SCI in
humans (Jackson et al., 2004) (www.nscisc.uab.edu).
The observation of improved grip-strength in LV-ChABC treated an-
imals is signiﬁcant when considering the potential translatability of this
treatment, since cervical SCI patients list improved upper limb and
hand functions as one of their highest priorities (Anderson, 2004).
These functions are both reﬂected well in the grip-strength test,
with improved paw function required to grip the apparatus properly
and improved upper limb function required to reach increased forces
of grip-strength.Whilst signiﬁcant functional improvementswere detect-
edusing thehorizontal ladder andgrip-strength tasks, no suchdifferences
were observed using the inclined plane task. Whilst this may simply be a
reﬂection of a lack of sensitivity using the inclined plane task, it may well
indicate that spinal pathways important for each of these tasks are affect-
ed to differing degrees. For instance, electrophysiological experiments
showed that there were dramatic improvements in the functionality of
the ascending sensory pathway; a pathway which, along with the
corticospinal tract, is known to be heavily involved in skilled locomotor
function as well as forelimb grip-strength (Sedy et al., 2008). Conversely,
neither of these pathways are thought to be important in performance
on the inclined plane task (Sedy et al., 2008). It would therefore be
interesting to assess if any improvements in pathways important
in inclined plane performance (such as vestibulospinal and
reticulospinal tracts) could be detected electrophysiologically in
order to determine if LV-ChABC is differentially affecting various
spinal pathways.
Thus, we present novel data that chondroitinase gene therapy leads
to signiﬁcant improvements in important functional and anatomical
outcome measures using a clinically representative cervical contusion
injury model. These results have important implications for the further
development of this treatment, indicating that if current attempts to im-
prove its safety proﬁle are successful, assessment in a larger animal
model (such as porcine, canine or primate) is likely to be an important
next step towards clinical translation (Ramer et al., 2014). Another in-
teresting future direction for this work will be to combine
chondroitinase gene therapy with a regime of rehabilitative techniques
aimed at further enhancing the observed improvements to upper limb
and hand function. This could be achieved through repetitive electrical
activation of spinal pathways important to upper limb function in ro-
dents (e.g. corticospinal tract) via implanted electrodes (Carmel et al.,
2010), in addition to more traditional behavioural rehabilitative tech-
niques speciﬁcally targeting and reinforcing complex movements of
the upper limbs (such as skilled reaching tasks) (Garcia-Alias et al.,
2009). Efﬁcacy of chondroitinase gene therapy treatment has now
been demonstrated in clinically relevant contusion injury models at
both thoracic and cervical levels. It will now be important to determine
if similar effects are observed in larger animal models and if its efﬁcacy
can be further enhanced by combination with additional therapeutic
strategies. These ﬁndings show promise for the further development
of chondroitinase gene therapy, as well as other strategies which target
CSPGs (Lang et al., 2015), as potential therapeutics for restoring function
following spinal cord injury.
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